Integumen PLC - Board Appointment & Admission of Shares
("Integumen" or "Company")
Appointment of RinoCloud MD, Fionán Murray, to the Board
Admission of New Ordinary Shares
Further to the Company's announcements on
"We thank our existing and new investors for their investment. Their continued support demonstrates confidence in our strategy and vision to grow Integumen into a leader in virtual microbiology testing company. Over the last five years, Labskin has established itself as an approved supplier of products and services into a large portfolio of blue-chip skincare, pharma, personal care, wound care and health care clients across the US, EU and
Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on extending digital services on top of existing Labskin physical services to rapidly grow the Labskin AI footprint.
As Managing Director of RinoCloud Fionán Murray oversaw the development of a range of software services dedicated to data management - its security, storage, curation and analysis - which generated interest from large blue-chip clients in Government, Financial Services,
· GDPR data management compliance for government;
· Secure data collaboration between large financial services groups and their customers/distribution channels;
· Secure data curation and collaboration for research and development groups; and
· Big science data analysis using AI.
These existing sales, marketing and distribution channels provide the opportunity for cross selling complementary digital and physical testing services currently being rolled out as part of the Labskin AI eco-system. This incorporates the data management and analytic services already built into Labskin AI by the RinoCloud integration.
Total Voting Rights
The issued share capital of the Company now comprises 953,173,684 Ordinary Shares with one voting right per share. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the
Further information in relation to Fionán Murray
Save for the information above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment Fionán Murray.
Full name: Fionán Murray
Age: 54 years old
In the last five years,
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
| || || |
+44 (0) 7340 055 643
| || |
+44 (0) 113 370 8974
| || |
+44 (0) 20 3621 4120
Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
This information is provided by RNS, the news service of the
Quick facts: DeepVerge PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE